CJC-1295 research guide

CJC-1295 in Amos — GHRH Analog Research Guide

CJC-1295 research guide for Amos. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.

Skip to Sourcing Guide Order CJC-1295 →

CJC-1295 in Amos — Research & Sourcing Guide

For anyone in Amos looking to source CJC-1295, the key fact to understand is that this compound is available only through an online research supply market. What this means for Amos researchers is that your location matters far less than your ability to evaluate vendor quality — and those quality checks are within reach of all serious researchers. What consistently distinguishes top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for safety screening. Use this guide to assess sourcing options methodically — the framework here apply whether you are in Amos or anywhere else.

How CJC-1295 Works — Mechanisms & Research

CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Amos comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.

How to Evaluate CJC-1295 Vendors

The first step for any Amos researcher sourcing CJC-1295 is identifying 2-3 vendors with documented positive community reputations — search results alone are too heavily influenced by marketing spend. When reviewing a CJC-1295 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are at acceptable levels for the intended application. For Amos researchers evaluating vendors with limited track records: a modest first purchase to test the product before committing to research quantities is standard practice in the community. For Amos researchers making a first CJC-1295 purchase: work through this evaluation framework first, start with a modest quantity, and verify batch traceability on arrival before use.

Order CJC-1295 — ships to Amos
COA-verified · International tracking · Research grade
Order Now →

CJC-1295 Safety, Handling & Research Protocols

As a research compound, CJC-1295 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and restricted human research data. Reconstitute CJC-1295 with bacteriostatic water at the concentration suited to your research design; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — or 25mcg per insulin syringe unit. The most significant preventable safety hazard in CJC-1295 research is endotoxin from inadequately tested product — a confirmed endotoxin test result in the lot-matched COA is the specific protection against this risk. For any individual considering CJC-1295 outside a formal research context: consult a qualified physician — this compound is unapproved for human therapeutic application and its risk profile is not equivalent to approved medications.

Frequently Asked Questions

What purity is required for CJC-1295 research?

CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.

What is CJC-1295?

CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.

Order CJC-1295 today
COA-verified · International shipping available
Order Now →